Last reviewed 2026-05-29 · How we verify

WR909390

U.S. Army Medical Research and Development Command · Phase 1 active Small molecule ✓ Verified May 2026

WR909390 is a Small molecule drug developed by U.S. Army Medical Research and Development Command. It is currently in Phase 1 development. Also known as: Triazine WR909390.

WR909390 is a novel triazine compound being studied in an exploratory microdose study for its pharmacokinetics and bioavailability. This study is assessing WR909390, along with two other compounds, WR826647 and WR909388, for potential use in treating malaria.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	WR909390
Also known as	Triazine WR909390
Sponsor	U.S. Army Medical Research and Development Command
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

WR909390 CI brief — competitive landscape report
WR909390 updates RSS · CI watch RSS
U.S. Army Medical Research and Development Command portfolio CI

Frequently asked questions about WR909390

What is WR909390?

WR909390 is a Small molecule drug developed by U.S. Army Medical Research and Development Command.

Who makes WR909390?

WR909390 is developed by U.S. Army Medical Research and Development Command (see full U.S. Army Medical Research and Development Command pipeline at /company/u-s-army-medical-research-and-development-command).

Is WR909390 also known as anything else?

WR909390 is also known as Triazine WR909390.

What development phase is WR909390 in?

WR909390 is in Phase 1.

Manufacturer: U.S. Army Medical Research and Development Command — full pipeline
Also known as: Triazine WR909390

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing